false
Catalog
2022 World Conference on Lung Cancer (ePosters)
EP16.03-042. BET Inhibitors Stimulate NK Cytotoxic ...
EP16.03-042. BET Inhibitors Stimulate NK Cytotoxic Activity in NSCLC through Attenuation of YAP/TAZ and SMAD3 Transcriptional Programs
Back to course
Pdf Summary
A recent study conducted by researchers in Italy explores the potential of BET inhibitors (BETi) in stimulating the cytotoxic activity of natural killer (NK) cells in non-small cell lung cancer (NSCLC). NK cells play a crucial role in immune surveillance against tumors, and their activation and cytotoxicity are regulated by a complex network of receptors. The study found that BETi treatment increased the immune response mediated by NK cells towards NSCLC. BETi enhanced the activation of NK cells and their ability to kill tumor cells. Additionally, BETi reprogrammed both tumor cells and NK cells by downregulating immune checkpoint ligands and receptors, respectively. The study identified the transcription factors YAP and TAZ as key regulators of BETi-dependent downregulation of immune checkpoint ligands in tumor cells and the transcription factor SMAD3 as a key regulator of BETi-dependent downregulation of immune checkpoint receptors in NK cells. Importantly, the study demonstrated that BETi treatment led to increased recognition and killing of tumor cells by NK cells. In in vivo experiments, the combination of BETi treatment and NK cell therapy resulted in a significant reduction in tumor growth. The findings of this study suggest that BET inhibitors have the potential to enhance the efficacy of immunotherapy treatments and NK cell-based therapies in NSCLC.
Asset Subtitle
Valentina Sancisi
Meta Tag
Speaker
Valentina Sancisi
Topic
Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapies
Keywords
BET inhibitors
NK cells
NSCLC
immune response
tumor cells
immune checkpoint ligands
immune checkpoint receptors
transcription factors
immunotherapy treatments
tumor growth
×
Please select your language
1
English